<DOC>
	<DOCNO>NCT02725177</DOCNO>
	<brief_summary>Treatment ACTHAR Gel result reduction ocular inflammation patient active ocular sarcoidosis require systemic immunosuppressant therapy ( hypothesis )</brief_summary>
	<brief_title>Ocular Sarcoidosis Open Label Trial ACTHAR Gel</brief_title>
	<detailed_description>The initial treatment ocular sarcoidosis usually rely combination topical glucocorticoid oral glucocorticoid , associate significant ocular systemic toxicity . Steroid-sparing therapy limit variable unpredictable efficacy , prolonged time clinical response , medication intolerance , difficulty obtain payor approval . As result , uncommon treat physician must choose excessive glucocorticoid toxicity versus poor control ocular inflammation . Ongoing ocular inflammation , turn , lead eventual visual loss occasionally blindness . There need reliable , expeditious therapy use alternative glucocorticoid sarcoidosis uveitis . Adrenocorticotropic hormone , activation melanocortin receptor leukocytes , dampen immune response non-glucocorticoid dependent mechanism . The propose study aim define whether effectiveness ACTHAR gel patient , delineate effect dose regimen , provide information safety approach moderate severe ocular sarcoidosis . ACTHAR 39-amino acid peptide natural form adrenocorticotropin hormone ( ACTH ) initially approved 1952 FDA . It since approve 19 indication include respiratory sarcoidosis , multiple sclerosis , infantile spasm .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Uveitis , Anterior</mesh_term>
	<mesh_term>Iridocyclitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>Patient sarcoidosis define ATS/ERS/WASOG guideline ( American Thoracic Society/European Respiratory Society /World Association Sarcoidosis Other Granulomatous Diseases ) Any posterior , intermediate panuveitis sufficient severity warrant therapy , opinion treat physician OR Anterior uveitis require 4 daily application topical corticosteroid maintain control inflammation , uncontrolled topical therapy Persistent disease activity ( active uveitis ) time screen Other cause ocular inflammation Uncontrolled diabetes , hypertension , contraindication increase dosage glucocorticoid Recent ( less 4 week ) intraocular intraorbital steroid injection Escalation immunosuppressive medication screen initiation study medication Severe extraocular sarcoidosis likely require additional therapy ( opinion investigator ) Administration investigational medication sarcoidosis within 3 month , 5 halflives , whichever longer Have history opportunistic infection within 6 month prior screen Have history malignancy , except fully resect cutaneous squamous cell cancer cutaneous basal cell cancer , cervical carcinoma insitu minimum 5 year period without recurrence Severe organ disease felt likely lead death within next six month Unable follow study protocol , include requisite travel followup ocular test Women childbearing potential must use adequate birth control measure ( abstinence , hormonal contraceptive , intrauterine device , barrier method spermicide , surgical sterilization ) must agree continue precaution , become pregnant plan pregnancy 6 month receive last treatment study agent . Women childbearing potential must test negative serum pregnancy test screening . Breastfeeding woman exclude participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Ocular Sarcoidosis</keyword>
</DOC>